



Current and Future Bladder Cancer Landscape

Guest Editor:

Prof. Dr. Leonardo O. Reis

1. UroScience, School of Medical Sciences, University of Campinas, UNICAMP, Campinas, Sao Paulo 13083-970, Brazil

2. Center for Life Sciences, Pontifical Catholic University of Campinas, PUC-Campinas, Sao Paulo 13087-571, Brazil

Deadline for manuscript submissions:

closed (31 August 2023)

Message from the Guest Editor

Dear Colleagues,

Urothelial carcinoma of the bladder is one of the most prevalent cancers worldwide, diagnosed as non-muscle invasive (NMIBC) in 75% of cases, in which cystoscopy, transurethral resection, and intravesical bacillus Calmette–Guérin (BCG) have withstood the test of time, remaining the gold standards, as well as neo-adjuvant cisplatin-based chemotherapy and cystectomy in the muscle-invasive context.

Since 2016, the bladder cancer treatment scenario has evolved with the introduction of monoclonal antibodies developed to specifically target immune checkpoint molecules, opening new diagnostic, prognostic, therapeutic, and epidemiological paradigms. This Special Issue will cover the present and future of this evolving landscape.

Prof. Dr. Leonardo O. Reis

Guest Editor

